Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Biomed Pharmacother ; 57(7): 274-7, 2003 Sep.
Article in English | MEDLINE | ID: mdl-14499172

ABSTRACT

Subjects with certain HLA alleles have a higher risk of specific autoimmune diseases than those without these alleles. The 8.1 ancestral haplotype (AH) is a common Caucasoid haplotype carried by most people who type for HLA-B8,DR3. It is unique in its association with a wide range of immunopathological diseases. To gain insight into the identification of the mechanism(s) of disease susceptibility of 8.1 AH carriers, we have investigated the prevalence of circulating immune complexes and non-organ-specific autoantibodies in healthy carriers of the haplotype. The results show that carriers of 8.1 AH display both a significant increased prevalence of immune complexes and higher titers of anti-nuclear autoantibodies. This AH carries a single segment characterized by no C4A gene. This null allele does not code for a functional C4A protein that likely plays an anti-inflammatory role being specialized in the opsonization and immunoclearance processes. So, this genetic defect has been claimed to allow that an increased production of autoantibodies directed vs. cells that have undergone apoptosis and are not efficiently disposed because a reduced antigenic clearance. The results obtained in the present study fit very well with this hypothesis. In the AH carriers the simultaneous high setting of tumor necrosis factor (TNF)-alpha may supply the autoantigens (providing an excess of apoptotic cells) that drive the autoimmune response. In conclusion, the C4 defect associated to the increased spontaneous release of TNF-alpha, modifying a certain number of immunological parameter may be the most characterizing feature of the 8.1 AH. In the majority of individuals, an autoimmune response clinically relevant will develop only in the presence of other immunological abnormalities.


Subject(s)
Autoimmune Diseases/etiology , Complement C4/genetics , HLA Antigens/genetics , Haplotypes/genetics , Adult , Alleles , Autoimmune Diseases/genetics , Autoimmune Diseases/immunology , Enzyme-Linked Immunosorbent Assay , Female , Gene Frequency/genetics , HLA-B8 Antigen/genetics , HLA-DR3 Antigen/genetics , Haplotypes/immunology , Humans , Male , Middle Aged
2.
J Infect Dis ; 186(12): 1835-9, 2002 Dec 15.
Article in English | MEDLINE | ID: mdl-12447771

ABSTRACT

Vgamma9/Vdelta2 T cells can contribute to protective immune response against Mycobacterium tuberculosis, although the extent to which and mechanisms by which they could actually protect against human tuberculosis remain unclear. We have previously reported that Vgamma9/Vdelta2 T cells from tuberculin purified protein derivative (PPD)-positive children, either healthy or affected by different clinical forms of tuberculosis, strongly proliferate to different phosphoantigens in vitro, whereas Vgamma9/Vdelta2 T cells from PPD-negative healthy subjects proliferate very poorly. We report here that Vgamma9/Vdelta2 T cells from tuberculous children have an increased proliferative activity, but decreased interferon (IFN)-gamma production and granulysin expression. After successful chemotherapy, the Vgamma9/Vdelta2 T cell proliferative response strongly decreased, whereas IFN-gamma and granulysin production consistently increased. Disease-associated changes in Vgamma9/Vdelta2 T cell effector functions in patients with tuberculosis are consistent with the possibility that these T cells may play a protective role in immune response against M. tuberculosis infection.


Subject(s)
Mycobacterium tuberculosis , Receptors, Antigen, T-Cell, gamma-delta/analysis , T-Lymphocytes/immunology , Tuberculosis/immunology , Adolescent , Antigens, Differentiation, T-Lymphocyte/biosynthesis , Antitubercular Agents/therapeutic use , Child , Child, Preschool , Female , Humans , Infant , Interferon-gamma/biosynthesis , Male , Tuberculin Test , Tuberculosis/blood , Tuberculosis/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...